Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis
Autor: | Hideki Iwahashi, Masashi Takano, Takahiro Sakamoto, Hiroko Matsuura, Tomoyuki Yoshikawa, Kenichi Furuya, Mika Kuwahara, Morikazu Miyamoto, Hiroaki Soyama, Kento Kato, Hiroki Ishibashi, Tadashi Aoyama, Kazuki Takasaki |
---|---|
Rok vydání: | 2018 |
Předmět: |
Adult
0301 basic medicine Cancer Research medicine.medical_specialty endocrine system diseases Bevacizumab Toxicology Deoxycytidine Gastroenterology 03 medical and health sciences 0302 clinical medicine Stable Disease Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Adverse effect Aged Retrospective Studies Aged 80 and over Ovarian Neoplasms Pharmacology business.industry Hazard ratio Middle Aged medicine.disease Gemcitabine Progression-Free Survival Regimen 030104 developmental biology Oncology Drug Resistance Neoplasm 030220 oncology & carcinogenesis Cohort Female Neoplasm Recurrence Local business Ovarian cancer medicine.drug |
Zdroj: | Cancer Chemotherapy and Pharmacology. 81:809-814 |
ISSN: | 1432-0843 0344-5704 |
DOI: | 10.1007/s00280-018-3552-5 |
Popis: | To compare a cohort of patients with platinum-resistant recurrent ovarian cancer (PROC) treated with bevacizumab and gemcitabine (Bev–Gem) to that of patients treated only with gemcitabine (Gem). Between 2011 and 2017, we identified the Bev–Gem and Gem PROC groups. The regimen included 1000 mg/m2 of Gem on days 1, 8, and 15, and 15 mg/m2 of Bev on day 1, every 4 weeks. Progression-free survival (PFS) and overall survival (OS) were calculated from the date of the administration of Bev–Gem or Gem until disease progression or death. The Bev–Gem and Gem groups included 18 and 29 patients, respectively. More patients had advanced stage disease in the Bev–Gem group (p = 0.048); no other characteristics differed between the groups. The response rates [ratio of complete remission (CR) to partial remission (PR)] of Bev–Gem and Gem were 38.9 and 3.4%, respectively (p |
Databáze: | OpenAIRE |
Externí odkaz: |